Lynette M Sholl

Lynette M Sholl, M.D.
Associate Pathologist, Brigham and Women's Hospital, Assistant Professor, Harvard Medical School,
Brigham and Women’s Hospital
Harvard Medical School
lmsholl@partners.org

Academic Profile at a Glance
Dr. Sholl
  •  Graduated from Johns Hopkins University in 1998
  • Graduated from Stanford University School of Medicine in 2003
  • Board Certified in Anatomic Pathology and Molecular Genetic Pathology 
  • Associate Director, Center for Advanced Molecular Diagnostics at Brigham and Women’s Hospital 
  • Chief, Pulmonary Pathology Division at Brigham and Women’s Hospital 
  • Editorial board, Human Pathology
  • Associate Editor, Histopathology
  • Section Editor, Archives of Pathology and Laboratory Medicine
Selected Publications
Sholl LM, Hornick, JL, Pinkus JL, Pinkus GS, Padera RF.  Immunohistochemical analysis of Langerin in Langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases.  Am J Surg Pathol.  2007; 31(6):947-952.

Sholl LM, Iafrate AJ, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol. 2007;20(10):1028-1035.

Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M Zhou, X, Comb MJ. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-3028.

Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.  Cancer Res. 2009; 69(21):8341-8348.

Sholl LM, Long KB, Hornick JL.  Sox2 expression in non small cell and pulmonary neuroendocrine carcinomas.  Appl Immunohistochem Mol Morphol. 2010; 18(1):55-61.

Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon A, Pan B-S, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met activation in Non-Small Cell Lung Cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.  Am J Pathol. 2010; 177(1):415-423.
Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon A, Pan B-S, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met activation in Non-Small Cell Lung Cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.  Am J Pathol. 2010; 177(1):415-423.

Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi L, Jackman, D,  Lee, C,  Jänne, P,  Lindeman, N. EGFR Mutation is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma than FISH, CISH, or Immunohistochemistry. Am J Clin Path. 2010; 133(6):922-934.

Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 Protein Expression Is an Independent Poor Prognostic Indicator in Stage I Lung Adenocarcinomas.  Am J Surg Pathol. 2010; 34(8):1193-1198.

Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, Gross BH, Oak SR, Coelho AL, Evanoff H, Day E, Toews GB, Joshi AD, Schaller MA, Waters B, Jarai G, Westwick J, Kunkel SL, Martinez FJ, Hogaboam CM. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med. 2010;2(57):57ra82.


Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM. Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum. Am J Surg Pathol. 2012 Aug;36(8):1222-1227.

Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, and Hornick JL.  Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas.  J Thor Oncol. 2013 March;8:322-328. [With editorial.]

Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, and Rodig S. ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas. Am J Surg Pathol.  2013 Sep;37(9):1441-1449.

Cagle PT, Sholl LM, Lindeman NI, Alsabeh R, Divaris D, Foulis P, Lee G, Neal J, Nowak J, Yu PP.  Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non-Small Cell Carcinoma of the Lung.  Archives Path Lab Med.  2014 Feb; 138(2):171-174. 

Doyle LA, Wong KK, Bueno R, Dal Cin P, Fletcher JA, Sholl LM, Kuo F.  Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. Cancer Genet. 2014 Jul-Aug;207(7-8):335-339.

MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI.  Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. J Mol Diagn. 2014 Nov;16(6):660-672.
 
Abo RP, Ducar M, Garcia EP, Thorner AR, Rojas-Rudilla V, Lin L, Sholl LM, Hahn WC, Meyerson M, Lindeman NI, Van Hummelen P, MacConaill LE.BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18;43(3):e19.

Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod Pathol. 2015 May;28(5):732-739.


Sholl LM*, Aisner DL*, Varella-Garcia M*, Berry LD*, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DA. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma:  The Lung Cancer Mutation Consortium experience.  J Thorac Oncol. 2015 May;10(5):768-777.
Sholl LM, Nishino M, Pokharel S, Mino-Kenudson M, French CA, Janne PA, Lathan C. Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. J Thorac Oncol. 2015 Jun;10(6):951-959.
Hwang DH, Sun H, Rodig SJ, Hornick JL, Sholl LM. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma. Histopathology. 2015 Jul;67(1):81-89.

Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Clin Cancer Res. 2015 March 3.  [Epub ahead of print]

Tanizaki J, Ercan D, Capelletti M, Dodge ME, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, Hammerman PS, Oxnard GR, Wong KK, Janne PA. Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2. Cancer Res. 2015 Jun 5. [Epub ahead of print]

Nishino M, Sholl LM, Hodi S.  Anti-PD-1 Related Pneumonitis during Cancer Immunotherapy. NEJM. 2015 Jul; 373(2):288-90. (Letter to the Editor)

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1726-35.

Gao X, Sholl LM, Nishino M, Heng JC, Jänne PA, Oxnard GR.Clinical Implications of Variant ALK FISH Rearrangement Patterns. J Thorac Oncol. 2015 Nov;10(11):1648-52.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Jan 4. [Epub ahead of print]
 
Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Jan 4. [Epub ahead of print]

Hwang DH, Sholl LM, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, MacConaill LE, Vivero M, Hornick JL, Kuo FC, Lindeman NI, Dong F. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2016 Jan 30. [Epub ahead of print]

Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach SL, Fontes C, Shi Y, Chalasani P, Janne PA. Clinical and molecular characteristics of NF1 mutant lung cancer. Clin Cancer Res. 2016 Feb 9 [Epub ahead of print]

 About Your Organization/Department
Brigham and Women’s Hospital is a large academic medical center located in Boston, Massachusetts. BWH provides pathology and molecular diagnostics services for Dana Farber Cancer Institute, the largest cancer center in New England.  
Over the last two and a half years, the Center for Advanced Molecular Diagnostics at BWH, together with DFCI and Boston Children’s Hospital, has sequenced over 11,000 tumors as part of the PROFILE initiative.  In addition to its cancer volume, BWH has an active multidisciplinary interstitial lung disease program and performs the largest volume of lung transplantations in New England.  

 Fun Facts
 Reformed long distance runner 

 Most important Achievement
Raising happy and healthy children